FOSTER CITY, Calif. (AP) – Gilead Science Inc.’s earnings tumbled 17 percent in first quarter as sales of its blockbuster hepatitis C franchise slowed faster than expected, missing Wall Street estimates.
The maker of Harvoni, the first once-daily, single-pill regimen for hepatitis C, said sales of the best-selling drug fell 15 percent to $3 billion in the quarter, with the steepest drop-off in the U.S. That decline was partially offset by slightly higher sales for an older hepatitis C drug, Sovaldi, which grew to $1.28 billion.
The company’s profit slipped to $2.53 per share, compared with $2.76 in the prior-year period. Adjusted for one-time costs and adjustments the company would have earned $3.03 per share. That was below the average forecast of Wall Street analysts who were looking for earnings of $3.12 per share, according to Zacks Investment research.
Gilead Sciences Inc., based in Foster City, California, has grown into one of the world’s biggest drugmakers thanks to its breakthrough treatments for hepatitis C, a liver destroying virus estimated to affect some 185 million people worldwide.
However use of the drug has been slowing in the U.S., where many of the patients who are eligible and able to afford the drugs have already received them. Unlike many pricey drugs that have to be taken continuously, Gilead’s drugs usually eliminate the virus after one round of therapy. Additionally, many private insurance plans and government health programs have been limiting which patients they will cover the drugs for, often waiting until the patients have suffered significant liver damage.
